
Conference Coverage
about 19 hours ago
Specialty Pharmacy's Expanding Role in IBD Care and Biosimilar Educationabout 20 hours ago
FDA, ASH Experts Review Newly Approved Therapies in Hemophiliaabout 21 hours ago
Rural Hospitals Face Mounting Pressures, ClosuresLatest News

A Cup of Coffee or Life-Saving Drugs: Shifting Decision-Making Practices in Health Care

How a New Generation of CAR T-Cell Therapies Could Reduce the Risk of Rejection

Pharmacist Strategies for Managing Comorbid Depression and Diabetes

Isa-VRd Regimen Demonstrates Robust Efficacy Across Age and Frailty Groups in Newly Diagnosed Multiple Myeloma

Pharmacy Deserts: A Crisis Health Care Providers Can Help Solve with Technology and Teamwork

Shorts










Podcasts
Videos
Continuing Medical Education
All News

Rural hospitals face a crisis, but pharmacists can expand services to alleviate the uninsured patient burden and enhance community health.

FDA approves Omisirge, the first cell therapy for severe aplastic anemia, offering hope for patients lacking donor matches and improving recovery rates.

Pharmacists play a crucial role in optimizing CAR-T therapy outcomes by guiding bridging therapy decisions and enhancing patient safety through proactive collaboration.

Pharmacist-led refill authorizations enhance outpatient care, reduce physician burnout, and streamline pharmacy management in health systems, improving patient satisfaction.

Pharmacists can contribute to the care of patients with multiple myeloma by managing cytokine release syndrome and encouraging vaccination when receiving anti-CD38 antibody treatment.

Experts discuss the complexities of gene therapy for sickle cell disease, emphasizing patient support, psychosocial factors, and long-term care considerations.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

Pharmacists play a crucial role in ensuring travelers receive essential vaccines, bridging gaps in immunization and enhancing global public health.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Although highly efficacious, patient selection and adverse event management are crucial.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend individual-based decision-making for parents when deciding when or if to give their child the birth dose of the hepatitis B virus vaccine.


Palbociclib Combination Is Safe, Efficacious in Patients With HER2-Positive Metastatic Breast Cancer
Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

The Emerging Practice Model Is Having a Moment in Popular Culture. What Is It and What Is the Role of Pharmacy?

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

Emerging pharmacy trends will be highlighted at the American Society of Health-System Pharmacists (ASHP) Midyear 2025, including AI innovations, GLP-1 therapies, and evolving geriatric and neonatal care.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

Research reveals low-dose cannabinoids, like THC, may enhance serotonin levels and combat chronic inflammation in HIV patients, offering new treatment possibilities.



































